期刊文献+

水飞蓟素对大鼠体内他莫昔芬药动学的影响 被引量:1

Effects of Silymarin on Pharmacokinetics of Tamoxifen in Rats
原文传递
导出
摘要 目的:研究水飞蓟素对大鼠体内他莫昔芬药动学的影响。方法:色谱柱为KromasilC18(250mm×4.6mm,5μm),流动相为乙腈-20mmol/LK2HPO4水溶液(70:30,V:V,磷酸调pH值至3.0),流速为1.0ml/min,柱温为45℃,检测波长λex=260nm,λem=375nm。对照组大鼠灌胃他莫昔芬丙二醇溶液(15mg/kg),实验组大鼠在灌胃水飞蓟素水溶液(70mg/kg)30min后灌胃他莫昔芬丙二醇溶液(15mg/kg)。测定不同时间2组大鼠血药浓度,以DAS2.1.1版药动学程序软件计算药动学参数。结果:与对照组比较,实验组的cmax显著增加(P<0.05),AUC0-36h和AUC0-∞分别增加了52.7%~80.1%和56.4%~82.1%(P=0.005),CL/F降低了29.5%~41.3%(P=0.005),而t1/2和tmax没有显著性差异。结论:水飞蓟素对大鼠体内他莫昔芬的药动学有显著影响,临床上二者合用时应注意潜在的药物相互作用。 OBJECTIVE:To study the effects of silymarin on pharmacokinetics of tamoxifen in rats.METHODS:The analysis was performed on a Kromasil C 18(250 mm×4.6 mm,5 μm)column,with the acetonitrile-20 mmol/L K 2 HPO 4(70:30,V:V,phosphoric acid to adjust the pH value to 3)as the mobile phase.The flow rate was 1.0 mL/min,Column temperature was 45 ℃,and the detective wave length were λ ex =260 nm,λ em =375 nm.Control group was given tamoxifen propylene glycol solution intragastrically(15 mg/kg);trial group was given silymarin solution 70 mg/kg,and received tamoxifen propylene glycol solution 15 mg/kg intragastrically 30 min later.Blood concentration of tamoxifen was determined by HPLC.The data were calculated by DAS2.0 software.RESULTS:Compared with control group,c max of tamoxifen in trial group was increased significantly(P〈0.05),AUC 0-36 h and AUC 0-∞ of tamoxifen was increased by 52.7%-80.1% and 56.4%-82.1%(P=0.005),respectively;CL/F of tamoxifen was decreased by 29.5%-41.3%(P=0.005),and no change of t max and t 1/2 was observed.CONCLUSIONS:There is significant effect of silymarin on tamoxifen in rats.Great importance should be attached to drug interaction during combined use of them in the clinic.
出处 《中国药房》 CAS CSCD 2013年第3期210-212,共3页 China Pharmacy
关键词 他莫昔芬 水飞蓟素 药动学 高效液相色谱法 Tamoxifen Silymarin Pharmacokinetics HPLC
  • 相关文献

参考文献9

  • 1叶魏武,王晓稼.三苯氧胺与乳腺癌防治研究进展[J].肿瘤研究与临床,2005,17(6):425-427. 被引量:3
  • 2孙素红,黄琴,曾峰.雌激素受体不同表达对局部晚期乳腺癌TC化疗方案的敏感性观察[J].中国药房,2009,20(20):1558-1559. 被引量:3
  • 3Jacolot F,Simon I,Dreano I,et al. Identification of thecytochrome P45o ID a family as the enzymes involved in then-demethylation of tamoxifen in human liver micro- somes[J]. Biochem Pharmacol, 1991,41(12):1 911.
  • 4Mani C, Gelboin HV,Park SS,et al Metabolism of theantimammary cancer antiestrogenic agent tamoxifentamo-xifen. I . Cytochrome P45o-catalysed N-demethylation and4-hydroxylation[J]. Drug Metab Dispos,1993,21 (4):645.
  • 5Rao US, Fine RL,Scarborough GA. Antiestrogens and st-eroid hormones : substrates of the human P-glycoprotein[J]. Biochem Pharmacol,1994,48(2) :287.
  • 6Bode JC. Silymarin for the therapy of liver disease[J]. AJG ,1999,94(2):545.
  • 7Kroll DJ,Shaw HS,Oberlies NH. Milk thistle nomencla-ture :why it matters in cancer research and pharmacokinet-ic studies[J]. Integr Cancer 2007,6(2) : 110.
  • 8Kim CS,Choi SJ, Park CY,et al Effects of silybinin onthe pharmacokinetics of tamoxifen and its active metabo-lite ,4-hydroxytamoxifen in rats[J]. Anticancer Res, 2010 ,30(2):79.
  • 9Golander Y, Sterason LA. Paired-ion chromatographic an-alysis of tamoxifen and two major metabolites in Plasma[J], JChromatogr,1980,181(1):41.

二级参考文献23

  • 1姜桂林.周剂量多烯紫杉醇联合顺铂治疗老年晚期非小细胞肺癌疗效观察[J].中国药房,2007,18(14):1096-1097. 被引量:4
  • 2陈灿铭,沈镇宙.乳腺癌新辅助化疗疗效预测因子的研究现状[J].循证医学,2007,7(3):132-134. 被引量:9
  • 3Jordan V C.Is tamoxifen the Rosetta Stone for breast cancer?[J].J Natl Cancer Inst,2003,95(5):338-340.
  • 4Wong Z W,Ellis M J.First-line endocrine treatment of breast cancer:aromatase inhibitor or antioestrogen?[J].Br J Cancer,2004,90(1):20-25.
  • 5EBCTCG.Tamoxifen for early breast cancer:An overview of the randomized trials[J].Lancet,1998,351(9114):1451-1467.
  • 6Mouridsen H,Gershanovich M,Sun Y,et al.Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:results of a phase Ⅲ study of the international letrozole breast cancer group[J].J Clin Oncol,2001,19(10):2596-2606.
  • 7Bonneterre J,Buzdar A,Nabholtz J M A,et al.Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma[J].Cancer,2001,92(9):2247-2258.
  • 8Buzdar A U.Datafrom the arimidex,tamoxifen,alone or in combination (ATAC) trial:implications for use ofaromatase inhibitors in 2003[J].Clin Cancer Res,2004,10(1):355S-361S.
  • 9Ellis M J.Neoadjuvant endocrine therapy as a drug development strategy[J].Clin Cancer Res,2004,10(1):391S-395S.
  • 10Rajkumar L,Guzman R C,Yang J,et al.Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments[J].Breast Cancer Res,2004,6(1):R31-37.

共引文献4

同被引文献12

  • 1李金恒.临床药物治疗监测的方法和应用[M].北京:人民卫生出版社,2003:28-39.
  • 2Kang P,Liao M,Wester MR,et al.CYP3A4-mediated carbamazepine(CBZ)metabolism:formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile[J].Drug Metab Dispos,2008,36(3):490.
  • 3Pauwels O.Factors contributing to carbamazepine-macrolide interactions[J].Pharmacological Research,2002,45(4):291.
  • 4Bjrnsson E,Olsson R.Outcome and prognostic markers in severe drug-induced liver disease[J].Hepatology,2005,42(2):481.
  • 5Luper S.A review of plants used in the treatment of liver disease:part 1[J].Altern Med Rev,1998,3(6):410.
  • 6Bode JC.Silymarin for the therapy of liver disease[J].American Journal of Gastroenterology,1999,94(2):545.
  • 7Beckmann-Knopp S,Rietbrock S,Weyhenmeyer R,et al.Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes[J].Pharmacology&Toxicology,2000,86(6):250.
  • 8Chang JC,Wu YT,Lee WC,et al.Herb-drug interaction of silymarin or silibinin on the pharmacokinetics of trazodone in rats[J].Chemico-Biological Interactions,2009(182):227.
  • 9van Erp NP,Baker SD,Zhao M,et al.Effect of milk thistle(silybum marianum)on the pharmacokinetics of irinotecan[J].Clinical Cancer Research,2005,11(21):7 800.
  • 10胡帆,袁洪,黄志军,左笑丛.水飞蓟素的药动学及药物相互作用[J].中国新药与临床杂志,2009,28(12):881-885. 被引量:2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部